CTNNB1 and endometrial cancer: As research advances, the integration of CTNNB1 mutation status into clinical practice holds promise for improving personalized treatment strategies for endometrial cancers, particularly when used alongside multi-targeted approaches and comprehensive biomarker panels [91].